AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

Q4 2024 Management View CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

AbbVie ABBV announced strong fourth-quarter 2024 results last week, beating estimates for both earnings and sales. While earnings of $2.16 per share declined around 22% year over year, sales rose 6.1% ...

AbbVie Inc. (NYSE:ABBV) shares are trading higher on Friday. The company reported fourth-quarter adjusted earnings per share ...

Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...

In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy over Humira and other currently leading treatment options, which should support combined annual sales of ...

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Raymond James analyst Gary Nachman raised the firm’s price target on AbbVie (ABBV) to $220 from $218 and keeps an Outperform rating on the ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...